Dublin, March 30, 2026 (GLOBE NEWSWIRE) — The “Non-Muscle Invasive Bladder Cancer Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The non-muscle invasive bladder cancer (NMIBC) market size has experienced robust growth, increasing from $3.66 billion in 2025 to an anticipated $4.82 billion by 2030. This expansion is driven by factors such as a rise in early diagnosis, enhanced use of transurethral resection, and increased adoption of immunotherapy and chemotherapy. Improvements in hospital pharmacy infrastructure and the development of online and retail pharmacy channels have also contributed significantly.
Personalized medicine is playing a crucial role in steering NMIBC market growth. This approach, which tailors treatment plans to an individual’s genetic makeup and lifestyle, is facilitated by advancing genomic research and enhanced diagnostic tools. Recent data from the Personalized Medicine Coalition indicated that the FDA approved 16 new personalized treatments for rare diseases in 2023, illustrating strong year-on-year growth.
Corporate developments continue to shape the NMIBC landscape. ImmunityBio Inc. received FDA approval for ANKTIVA (N-803) in March 2024 for BCG-unresponsive patients, highlighting the importance of innovative immunotherapies. ANKTIVA, an IL-15 agonist, stimulates immune cells to attack cancerous cells. Additionally, a partnership between Ferring Pharmaceuticals and SK Pharmteco aims to bolster the production of Adstiladrin, a gene therapy to treat high-risk NMIBC.
The competitive landscape is rich with leading companies like Johnson & Johnson, Merck & Co Inc, AstraZeneca plc, and many others spearheading innovation and driving market dynamics. These companies are pivotal in the development and distribution of effective therapies and are crucial to market competitiveness.
In regional context, North America led the market in 2025, but Asia-Pacific is forecasted to exhibit the fastest growth through the next decade. Global market coverage spans across developed and emerging economies, inclusive of major players in Western Europe, Eastern Europe, and South America.
Reasons to Purchase:
- Gain an in-depth global perspective encompassing 16 geographies.
- Determine the impact of macro factors like geopolitical conflicts, trade policies, inflation, and regulatory changes.
- Formulate regional strategies based on detailed local data and analysis.
- Identify high-growth segments for strategic investment.
- Leverage forecast data and market drivers for competitive advantage.
- Understand consumer insights through end-user analysis.
- Benchmark against competitors using metrics such as market share and brand strength.
- Evaluate market potential with TAM and market attractiveness scores.
- Access comprehensive, high-quality data for internal and external presentations.
- Receive report updates with current data and an Excel dashboard for analysis.
Report Scope:
- Markets Covered: By Stage, Treatment, Tumor, and End-User categories.
- Companies Mentioned: Includes industry leaders like Johnson & Johnson; Merck & Co Inc; AstraZeneca; Genentech Inc; and more.
- Countries Covered: Covers a wide geographic span including Australia, Brazil, China, France, Germany, and more.
- Regions: Diverse regions analyzed include Asia-Pacific, Southeast Asia, Europe, North and South America, Middle East, and Africa.
- Time Series: Encompasses five years of historical data and ten years of forecasts.
- Data and Sourcing: Includes market growth ratios, GDP comparisons, and competitive market shares, all sourced via end notes.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $3.87 Billion |
| Forecasted Market Value (USD) by 2030 | $4.82 Billion |
| Compound Annual Growth Rate | 5.6% |
| Regions Covered | Global |
The companies featured in this Non-Muscle Invasive Bladder Cancer market report include:
- Johnson & Johnson
- Janssen Research & Development LLC
- Merck & Co Inc
- AstraZeneca plc
- Astellas Pharma US Inc
- EMD Serono Inc
- Genentech Inc
- Aura Biosciences Inc
- UroGen Pharma Ltd
- Protara Therapeutics Inc
- Istari Oncology Inc
- Heat Biologics Inc
- Viventia Bio Inc
- ImmunityBio Inc
- Altor BioScience Corporation
- SURGE Therapeutics Inc
- Pfizer Inc
- Hoffmann-La Roche Ltd
- CG Oncology Inc
- Tyra Biosciences Inc
- Prokarium Ltd
- ImmVira Pharma Co Ltd
- Trigone Pharma Ltd
- enGene Holdings Inc
- Atonco Pharma Ltd
For more information about this report visit https://www.researchandmarkets.com/r/5lfrn7
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Non-Muscle Invasive Bladder Cancer Market
